Shenzhen Geno-Immune initiates trial on cfMSCs for immune-related disorders
A clinical trial is evaluating the safety and efficacy of clonal fetal mesenchymal stem cells for immune-related disorders.
Asset / Drug
Drug and asset intelligence for Shenzhen with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Stem Cell Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.